Home

temperamento Hermana Transformador nmd pharma thomas hilm Moviente Amigo Transistor

Your career — NMD Pharma
Your career — NMD Pharma

Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy:  Results from a 12 month, double-blind, randomized pl
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized pl

NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn

NMD Pharma
NMD Pharma

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders

NMD Pharma ApS Annual Report for 1 January - 31 December 2017
NMD Pharma ApS Annual Report for 1 January - 31 December 2017

PRESS RELEASE NMD Pharma Moves Corporate Headquarters to INCUBA to Support  Future Growth
PRESS RELEASE NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth

NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma
NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma

Management team — NMD Pharma
Management team — NMD Pharma

Management team — NMD Pharma
Management team — NMD Pharma

NMD Pharma
NMD Pharma

NMD Pharma - Inkef capital
NMD Pharma - Inkef capital

Your career — NMD Pharma
Your career — NMD Pharma

Katja Krustrup Pedersen - Research Scientist and Project Manager - NMD  Pharma | LinkedIn
Katja Krustrup Pedersen - Research Scientist and Project Manager - NMD Pharma | LinkedIn

Management team — NMD Pharma
Management team — NMD Pharma

NMD Pharma - PIR International
NMD Pharma - PIR International

NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance  Treatments of Neuromuscular Disorders
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders

Management team — NMD Pharma
Management team — NMD Pharma

NMD Pharma - PIR International
NMD Pharma - PIR International

NMD Pharma - Inkef capital
NMD Pharma - Inkef capital

Management team — NMD Pharma
Management team — NMD Pharma

HITTA ER ET A UN AMI TA ON HI HA UT ME AT THE
HITTA ER ET A UN AMI TA ON HI HA UT ME AT THE

ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing

Patient Dosing Begins in Early Trial of Oral NMD670 for Myasthenia Gravis
Patient Dosing Begins in Early Trial of Oral NMD670 for Myasthenia Gravis

NMD Pharma - Inkef capital
NMD Pharma - Inkef capital

NMD Pharma Information | NMD Pharma Profile
NMD Pharma Information | NMD Pharma Profile